Arbutus Biopharma combines elite quality and profitability metrics with a strong earnings beat streak, but shares sit near the resistance-based target with a negative risk/reward setup and a small-cap sizing constraint that together argue for trimming rather than adding.
Thesis pillars
- High Quality Compounder Metrics→Stable
- Negative Asymmetry Near Target→Stable
- Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
Arbutus Biopharma Corporation (ABUS) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $4.80 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Counterparty: Moderna.
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B, led by imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, alongside a licensed lipid nanoparticle (LNP) patent portfolio asserted against... Read more
Sell if holding. Analyst target reached at $4.80 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Counterparty: Moderna. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Arbutus Biopharma Corporation
About Arbutus Biopharma Corporation
Arbutus Biopharma's lead clinical program, imdusiran (AB-729), is a subcutaneous RNAi therapeutic that produced functional cures in a subset of chronic hepatitis B patients across Phase 1 and Phase 2a trials enrolling over 200 patients, while AB-101, an oral PD-L1 inhibitor, sits in early Phase 1a/1b testing under an FDA clinical hold on its IND. In March 2026, Arbutus and licensing partner Genevant settled lipid nanoparticle patent litigation with Moderna for a $950 million payment, of which Arbutus is entitled to 20%.
Arbutus generates revenue primarily through licensing agreements rather than product sales, including a dependence on its license with Alnylam Pharmaceuticals for the commercialization of ONPATTRO (patisiran), and expects to depend on similar licensing and royalty arrangements for a significant portion of revenue for the foreseeable future. The company's clinical pipeline is funded in part by intellectual property litigation proceeds: beyond the pending Moderna settlement, Arbutus continues to pursue a separate patent infringement lawsuit against Pfizer and BioNTech over the same lipid nanoparticle delivery technology used in COVID-19 mRNA vaccines. On the clinical side, imdusiran has been evaluated in combination with interferon and, through a since-curtailed collaboration with Barinthus Biotherapeutics, with the immunotherapeutic VTP-300, after Barinthus paused further development of VTP-300 in January 2025. In 2025, Arbutus cut its workforce by an additional 57%, closed its Warminster, Pennsylvania headquarters and ended in-house discovery research to focus resources on imdusiran and AB-101.
Show full overview
Arbutus's near-term financial picture now hinges less on its cHBV pipeline than on litigation proceeds: the Moderna settlement's $950 million payment is due by July 8, 2026, but an additional $1.3 billion contingent payment depends on a still-pending Section 1498 appeal ruling, and the company is separately still litigating unlicensed LNP use against Pfizer and BioNTech with no trial date yet scheduled. Clinically, AB-101 remains under an FDA clinical hold on its IND, and imdusiran has not progressed beyond Phase 2a, leaving functional-cure rates in the 25-53% range across trial cohorts as the primary clinical evidence supporting the program.
See also: Healthcare · Biotechnology
From Arbutus Biopharma Corporation's most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyModerna10-K Item 1: 'Moderna will make an aggregate $950.0 million noncontingent lump sum payment (the Noncontingent Settlement Payment) to us and Genevant on or before July 8, 2026.'
- MEDIUMcounterpartyAlnylam Pharmaceuticals10-K Item 1A: 'We depend on our license agreement with Alnylam Pharmaceuticals, Inc. for the commercialization of ONPATTRO™ (Patisiran).'
Material Events(8-K, last 90d)
- 2026-05-27Item 5.02LOWShareholders approved the 2026 Omnibus Share and Incentive Plan at the Annual General Meeting, replacing prior equity plans. Routine compensation-plan approval, not a personnel departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $4.80 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Counterparty: Moderna. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.49. Score 6.4/10, moderate confidence.
Take-profit target: $4.86 (+0.6% upside). Prior stop was $4.49. Stop-loss: $4.49.
Concentration risk — Counterparty: Moderna; Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.5): -1.0.
Arbutus Biopharma Corporation trades at a P/E of 5.9 (forward -29.5). TrendMatrix value score: 8.4/10. Verdict: Sell.
9 analysts cover ABUS with a consensus score of 4.2/5. Average price target: $5.
What does Arbutus Biopharma Corporation do?Arbutus Biopharma is a clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B, led by...
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B, led by imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, alongside a licensed lipid nanoparticle (LNP) patent portfolio asserted against Pfizer/BioNTech and, until settled, Moderna. In March 2026 the company and licensing partner Genevant settled with Moderna for a 20% share of a $950 million upfront payment plus a share of a $1.3 billion contingent payment.